AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Understand this faster with AI
SA Transcripts159.09K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call AbCellera Biologics Inc. (ABCL) 2026 KeyBanc Capital Markets Healthcare Virtual Forum March 17, 2026 9:00 AM EDT Company Participants Martin Hogan - Senior Director of Strategic Finance & IR Conference Call Participants Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Presentation Scott SchoenhausKeyBanc Capital Markets Inc., Research Division Great. Thank you, everyone, for attending our Virtual Healthcare Forum. I'm Scott Schoenhaus, health care tech analyst here at KeyBanc. Wrapping it up for today, last fireside chat, Martin Hogan, who is the Senior Director of Strategic Finance and Investor Relations at AbCellera. Question-and-Answer Session Scott SchoenhausKeyBanc Capital Markets Inc., Research Division Martin, we have probably a lot of new investors to your story, and there's a lot of heightened interest and new interest on tech-enabled drug discovery. So maybe give a brief background on AbCellera and its platform, where you guys have been over the last several years and where you are today? Martin HoganSenior Director of Strategic Finance & IR Absolutely. Well, first of all, Scott, thanks so much for hosting us. Pleasure to be at your forum again. I will be making some forward-looking statements, so please consult our SEC filings for risk factors and other notes around that. Yes, we've been on a really exciting journey that now stretches for about 13 years, where for the first -- easily for the first decade, we made significant technology investments, building out capabilities to go from target nomination to now manufacturing drug product for antibody-based therapeutics with a very heavy focus initially around several core technologies where we would say the -- what allowed us to get going on this journey was technological differentiation in drug discovery and the investments that we've made since then and the experience that we've built in over 100 drug discovery programs have allowed us to build an